Innovative approaches in the field of advanced therapies are increasing rapidly so it is no surprise it is an area of growing deal flow, investment and intellectual property activity. This session will cover the current advanced therapy IP landscape and what emerging companies can do to provide potential R&D partners and investors with reassurance that the asset they are developing has a robust IP position. In an interactive manner speakers will discuss issues such as expectations around what an acceptable IP strategy looks like, how extensive Freedom to Operate searches should be and what the options are if conflicting third-party IP is identified.

Agenda:

14.00 – Registration and tea/coffee
14.30 – Welcome
14.35 – Setting the scene – Navigating the IP Landscape in Advanced Therapies
Will Arends, Marks & Clerk
14.55 – Panel Discussion: The IP Considerations in Dealmaking  
Moderator – Soren Demin, PharmaVentures
Panellists will include:
Michael Murray, Murray International Partners
Andrew Osborne, Ikarovec
Anji Miller, LifeArc
Will Arends, J A Kemp
Bradley Hardiman
15.45 – Closing Remarks
15.50 – Networking
16.30 – Close

Prices:
Members: Free
Non-members: £50 +VAT
Academics: please contact info@onenucleus.com